Alkermes (ALKS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
13 May, 2026Executive summary
Annual general meeting scheduled for May 20, 2026, with voting open to shareholders of record as of March 13, 2026.
Employees who are shareholders are encouraged to vote before the deadline of May 19, 2026, at 11:59 p.m. ET.
Voting matters and shareholder proposals
Proxy Statement includes a series of proposals for shareholder consideration and voting.
Board recommendations on each proposal are provided in the Proxy Statement.
Shareholder rights and capital structure
All employees holding shares as of the record date are entitled to vote at the annual meeting.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Alkermes
- Q1 2026 revenue up 28% to $392.9M, but Avadel costs drove a $66.5M net loss.ALKS
Q1 20265 May 2026 - Director elections, say-on-pay, auditor ratification, and share issuance authority up for vote.ALKS
Proxy filing6 Apr 2026 - Strong 2025 performance, governance enhancements, and key proposals mark this annual proxy.ALKS
Proxy filing6 Apr 2026 - Annual meeting to vote on directors, executive pay, auditor, equity plan, and share issuance.ALKS
Proxy filing27 Mar 2026 - Orexin agonists advance with flexible dosing, durable efficacy, and new indications in sleep and fatigue.ALKS
Stifel 2026 Virtual CNS Forum17 Mar 2026 - Major advances in sleep medicine and orexin pipeline drive growth and future opportunities.ALKS
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - 2026 outlook projects strong revenue growth, LUMRYZ integration, and pipeline advancement.ALKS
Q4 202525 Feb 2026 - Orexin program advances in phase 2, targeting narcolepsy and broader CNS disorders.ALKS
7th Annual Evercore ISI HealthCONx Healthcare Conference3 Feb 2026 - Proprietary product sales rose 16% year-over-year, driving robust Q2 profitability.ALKS
Q2 20243 Feb 2026